Compare DCGO & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCGO | XLO |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.5M | 56.9M |
| IPO Year | 2020 | 2021 |
| Metric | DCGO | XLO |
|---|---|---|
| Price | $0.36 | $8.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $2.38 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 1.1M | 9.5K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $322,196,000.00 | $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.77 | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $0.35 | $0.46 |
| 52 Week High | $1.65 | $9.90 |
| Indicator | DCGO | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 47.21 |
| Support Level | $0.35 | $8.52 |
| Resistance Level | $0.69 | $9.22 |
| Average True Range (ATR) | 0.03 | 0.29 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 8.36 | 53.33 |
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has two reporting segments: Mobile Health Services and Transportation Services. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.